Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FCX-007 / Precigen, Paragon Biosci
DEFI-RDEB, NCT04213261: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa	Active, not recruiting	3	6	US	FCX-007 (dabocemagene autoficel; see below for FCX-007 description)	Castle Creek Biosciences, LLC.	Recessive Dystrophic Epidermolysis Bullosa	01/23	07/37
RDEB, NCT02810951: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa	Terminated	1/2	6	US	FCX-007, Genetically-Modified Autologous Human Dermal Fibroblasts	Castle Creek Biosciences, LLC.	Epidermolysis Bullosa Dystrophica, Recessive	09/20	04/22